tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

AbCellera doses first participants in Phase 1 trial of ABCL575

AbCellera (ABCL) announced it has dosed the first participants in its Phase 1 clinical trial of ABCL575, an investigational antibody therapy being developed for the treatment of moderate-to-severe atopic dermatitis. ABCL575 is an Fc-silenced, half-life extended antibody that targets OX40 ligand. The randomized, placebo-controlled, double-blind study will assess safety and tolerability in healthy participants. Data from this study is expected in mid 2026.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1